Wright J O, Hiratzka L F, Brandt B, Doty D B
J Thorac Cardiovasc Surg. 1982 Jul;84(1):138-44.
Thrombosis of the Björk-Shiley prosthetic cardiac valve may occur in any valve position and regardless of anticoagulant status. Four illustrative cases are presented to demonstrate management problems. Review of cases reported in the literature suggests the minimal incidence of thrombosis of Björk-Shiley prostheses is about 2% in the aortic position and about 4% in the mitral position. Prevention of this complication appears to require continuous systemic anticoagulation with warfarin; even temporary interruption or alteration of anticoagulant regimen may be detrimental. Although changes in anticoagulation may rarely precipitate sudden thrombosis, in most cases a period averaging 10 months is required for pannus of organized thrombus to build up enough to cause acute thrombosis and malfunction of the valve. Operation to remove thrombus or replace the prosthesis is usually required for left-sided cardiac prostheses, but thrombosed valves in the tricuspid position may be successfully treated with fibrinolytic medical therapy.
Björk-Shiley人工心脏瓣膜血栓形成可发生于任何瓣膜位置,且与抗凝状态无关。现介绍4例说明性病例以展示管理问题。对文献报道病例的回顾表明,Björk-Shiley人工瓣膜血栓形成的最低发生率在主动脉瓣位约为2%,在二尖瓣位约为4%。预防这一并发症似乎需要用华法林持续进行全身抗凝;即使抗凝方案的暂时中断或改变也可能有害。尽管抗凝变化很少会突然引发血栓形成,但在大多数情况下,平均需要10个月的时间,机化血栓的血管翳才能积聚到足以导致急性血栓形成和瓣膜功能障碍。左侧心脏人工瓣膜通常需要进行手术清除血栓或更换人工瓣膜,但三尖瓣位血栓形成的瓣膜可用纤维蛋白溶解药物治疗成功。